'New drugs to prevent tuberculosis in the offing'

Image
Press Trust of India London
Last Updated : Oct 09 2018 | 4:40 PM IST

Researchers have identified a novel regulatory mechanism, which when deactivated, results in the death of tuberculosis pathogen, an advance that could pave the way for new drugs to prevent the life-threatening disease.

According to the World Health Organization (WHO), tuberculosis claimed over 1.3 million lives in 2016, said researchers from the University of Leicester in the UK.

The causative agent of tuberculosis, Mycobacterium tuberculosis, is a highly successful pathogen which can survive and grow in humans for decades, according to the study published in the journal Cell Reports.

M tuberculosis is a slow growing bacterium with a very thick and complex cell wall that is resistant to many common antibiotics, requiring the development of new drugs and approaches in order to stop the deadly disease.

"M tuberculosis is a nasty pathogen which is very difficult to treat because of its unique biology," said Galina Mukamolova from the University of Leicester.

"However, our research revealed weakness and vulnerable sides of this pathogen. We have shown that inactivation of just one protein can result in dramatic consequences.

"We can interfere into the very sophisticated mechanism for regulation of cell wall biosynthesis described in our study in order to kill M tuberculosis," Mukamolova said.

The team examined a protein called protein kinase B (PknB) found in M tuberculosis and found the reasons why it is necessary for growth in the pathogen.

PknB has been known for many years and extensively studied by many scientific groups.

Previously, scientists showed that it was somehow involved in regulation of cell wall biosynthesis, however the precise mechanism was not clear.

"We have shown that CwlM, another protein required for M tuberculosis growth, is the main protein which is phosphorylated by PknB," said Mukamolova.

"This function makes PknB indispensable for the growth of M tuberculosis. We found that two forms of CwlM (phosphorylated and non-phosphorylated) coexist in growing bacteria in different cellular compartments and may regulate different arms of the same process," Mukamolova said.

The research suggests that inactivation of CwlM, for example by using novel drugs, would result in death and lysis of M tuberculosis, researchers said.

This is an excellent target for new drug development, which is particularly important because of tuberculosis' rising resistance to existing drugs, they said.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Oct 09 2018 | 4:40 PM IST

Next Story